Edwards Lifesciences Corp
Change company Symbol lookup
Select an option...
EW Edwards Lifesciences Corp
COP ConocoPhillips
FBP First Bancorp
PTCT PTC Therapeutics Inc
ROKU Roku Inc
WORK Slack Technologies Inc
ARKW ARK Next Generation Internet ETF
SPOT Spotify Technology SA
GBTC Grayscale Bitcoin Trust (BTC)
ARKK ARK Innovation ETF
Go

Health Care : Health Care Equipment & Supplies | Large Cap Growth
Company profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World. Its products are categorized into three areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care. It also develops hemodynamic monitoring systems that are used to measure a patient's cardiovascular function in the hospital setting. It is developing products, such as the Edwards SAPIEN 3 Ultra System and Edwards SAPIEN XT transcatheter heart valve, among others. Its Transcatheter Heart Valve Therapy and Surgical Heart Valve Therapy products are manufactured in the United States, Singapore and Switzerland. Critical Care products are manufactured in its facilities located in Puerto Rico and the Dominican Republic.

Closing Price
$87.87
Day's Change
0.38 (0.43%)
Bid
--
Ask
--
B/A Size
--
Day's High
88.15
Day's Low
86.84
Volume
(Heavy Day)
Volume:
3,128,902

10-day average volume:
2,258,643
3,128,902

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Mesoblast Limited of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 7, 2020 - MESO

8:29 pm ET November 24, 2020 (Newsfile) Print

New York, New York--(Newsfile Corp. - November 24, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Mesoblast Limited ("Mesoblast") (NASDAQ: MESO) between April 16, 2019 and October 1, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the the United States District Court for the Southern District of New York. To get more information go to:

https://www.zlk.com/pslra-1/mesoblast-limited-loss-submission-form?prid=11201&wire=5

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7091/68921_345382_logo.jpg

The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) comparative analyses between Mesoblast's Phase 3 trial and three historical studies did not support the effectiveness of the Company's lead product candidate, remestemcel-L, for steroid refractory acute graft versus host disease due to design differences between the four studies; (2) as a result, the US Food and Drug Administration was reasonably likely to require further clinical studies; (3) as a result, the commercialization of remestemcel-L in the U.S. was likely to be delayed; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

If you suffered a loss in Mesoblast you have until December 7, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/68921

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.